Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

20.54
+0.14000.69%
Post-market: 20.30-0.2357-1.15%19:30 EDT
Volume:1.06M
Turnover:21.53M
Market Cap:1.32B
PE:-5.92
High:20.71
Open:20.38
Low:19.64
Close:20.40
52wk High:23.19
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.96
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:4.11
PE(LYR):-5.52

Loading ...

Cullinan Management (CGEM) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

Cullinan Therapeutics Shares Reverse Premarket Course; Last Down 4.2%

THOMSON REUTERS
·
Aug 13

Sector Update: Healthcare Stocks Advance Pre-Bell Thursday

MT Newswires Live
·
Aug 13

Cullinan Therapeutics Price Target Raised to $42.00/Share from $39.00 by Wedbush

Dow Jones
·
Aug 13

Wedbush Adjusts PT on Cullinan Therapeutics to $42 From $39, Maintains Outperform Rating

MT Newswires Live
·
Aug 13

Cullinan Therapeutics Shares Rise 12.3% Premarket After Lung Cancer Drug Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Aug 13

Cullinan Therapeutics, - Zipalertinib Arm Shows Significant Improvement in Progression-Free Survival with Manageable Safety

THOMSON REUTERS
·
Aug 13

Cullinan Therapeutics, - Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial

THOMSON REUTERS
·
Aug 13

Cullinan Therapeutics, - Taiho Oncology, Taiho Pharmaceutical, Cullinan Therapeutics to Pursue U.S. Regulatory Approval for Zipalertinib Combination

THOMSON REUTERS
·
Aug 13

Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal

Reuters
·
Aug 13

Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint in Planned Interim Analysis of Phase 3 Rezilient3 Trial

Reuters
·
Aug 13

Cullinan Says Zipalertinib Plus Chemotherapy Meets PFS Endpoint in Phase 3 Rezilient3 Lung Cancer Trial

Reuters
·
Aug 13

Analysts Are Bullish on These Healthcare Stocks: Mesoblast Limited (MEOBF), Cullinan Management (CGEM)

TIPRANKS
·
Aug 07

Cullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target

TIPRANKS
·
Aug 07

Wedbush Adjusts Price Target on Cullinan Therapeutics to $39 From $37, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Cullinan Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate

Benzinga Earnings
·
Aug 06

Cullinan Therapeutics Q2 Operating Income USD -57.254 Million Vs. IBES Estimate USD -57.1 Million

Reuters
·
Aug 06

Cullinan Q2 FY26 Net Loss Narrows 23.36% to $53.7 Million

Reuters
·
Aug 06

Cullinan Therapeutics Q2 Cash & Investments USD 356 Million

THOMSON REUTERS
·
Aug 06